Prelude Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-83,004
| Closed | -$1.26M | – | 1889 |
|
|
2022
Q3 | $1.26M | Buy |
+83,004
| New | +$965K | 0.05% | 348 |
|
|
2020
Q3 | – | Sell |
-14,786
| Closed | -$218K | – | 2521 |
|
|
2020
Q2 | $218K | Buy |
14,786
+3,880
| +36% | +$57.4K | 0.01% | 716 |
|
|
2020
Q1 | $147K | Sell |
10,906
-9,039
| -45% | -$171K | 0.01% | 505 |
|
|
2019
Q4 | $482K | Buy |
+19,945
| New | +$413K | 0.02% | 570 |
|
|
2019
Q3 | – | Sell |
-236
| Closed | -$7K | – | 2190 |
|
|
2019
Q2 | $7K | Sell |
236
-26,577
| -99% | -$1.02M | ﹤0.01% | 1476 |
|
|
2019
Q1 | $1.27M | Buy |
26,813
+12,661
| +89% | +$557K | 0.07% | 276 |
|
|
2018
Q4 | $511K | Sell |
14,152
-18,920
| -57% | -$888K | 0.03% | 464 |
|
|
2018
Q3 | $2.04M | Sell |
33,072
-6,246
| -16% | -$402K | 0.12% | 185 |
|
|
2018
Q2 | $2.66M | Sell |
39,318
-17,623
| -31% | -$986K | 0.17% | 99 |
|
|
2018
Q1 | $3.09M | Buy |
56,941
+24,974
| +78% | +$1.4M | 0.22% | 72 |
|
|
2017
Q4 | $1.91M | Buy |
31,967
+14,306
| +81% | +$868K | 0.15% | 138 |
|
|
2017
Q3 | $858K | Buy |
17,661
+2,858
| +19% | +$156K | 0.08% | 270 |
|
|
2017
Q2 | $778K | Sell |
14,803
-8,534
| -37% | -$397K | 0.07% | 251 |
|
|
2017
Q1 | $1.06M | Sell |
23,337
-7,352
| -24% | -$328K | 0.1% | 222 |
|
|
2016
Q4 | $1.16M | Sell |
30,689
-34,539
| -53% | -$1.31M | 0.14% | 182 |
|
|
2016
Q3 | $2.46M | Buy |
+65,228
| New | +$1.44M | 0.26% | 74 |
|
|
2015
Q2 | – | Sell |
-10,936
| Closed | -$343K | – | 2138 |
|
|
2015
Q1 | $343K | Buy |
+10,936
| New | +$317K | 0.05% | 464 |
|
Prelude Capital Management's AERI Position: Q4 2022 in Review
Prelude Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 83,004 shares — an estimated $1.26M sold.
Prelude Capital Management first reported a position in AERI in Q1 2015 and held it in 17 quarters. The position peaked at $3.09M in Q1 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Prelude Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Prelude Capital Management sold 83,004 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.26M.
- Prelude Capital Management first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 17 quarters.
- Prelude Capital Management's Aerie Pharmaceuticals position peaked at $3.09M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.